Cell Therapeutics Shows Positive Phase II/III Data For Pixantrone At ASH Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm plans 2H 2008 NDA for aggressive non-Hodgkin’s lymphoma, CEO Bianco tells “The Pink Sheet” DAILY.